Journal: Cancer Medicine

Article Title: CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/β‐catenin signaling pathway

doi: 10.1002/cam4.1960

Figure Lengend Snippet: Expression of CUL4B in human HNSCC. A, qRT‐PCR analysis of CUL4B mRNA in HNSCC tissues (tumor) and paired normal tissues (normal). B, qRT‐PCR analysis of CUL4B mRNA in male and female HNSCC tissues. C, CUL4B protein level in HNSCC tissues and paired normal tissues were assessed by Western blotting. D, Immunohistochemistry of CUL4B in nontumor and primary HNSCC tissue arrays. Scale bar: 50 μm. E, Kaplan‐Meier analysis of overall survival for patients with HNSCC. The analyses were conducted based on the immunohistochemistry of CUL4B and the survival information provided by the supplier. * P < 0.05

Article Snippet: The human HNSCC tissue microarrays (paraffin‐embedded), including follow‐up survival information, were provided by SuperBioChips.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Immunohistochemistry

Journal: Cancer Medicine

Article Title: CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/β‐catenin signaling pathway

doi: 10.1002/cam4.1960

Figure Lengend Snippet: Effects of CUL4B on malignant phenotypes in HNSCC cells. A, Cell viability of JHU‐012 cells transfected with vector or CUL4B was analyzed by MTS assays at different time points. B, Cell viability of sh con or sh CUL4B JHU‐012 cells was analyzed by MTS assays at different time points. C, Effects of CUL4B overexpression on anchorage‐dependent colony formation. Scale bar: 10 mm. D, Effects of CUL4B knockdown on anchorage‐dependent colony formation. Scale bar: 10 mm. E, CUL4B overexpression regulated transwell cell invasion and F, Matrigel invasion. Scale bar: 50 μm. G, CUL4B knockdown regulated transwell cell invasion and H, Matrigel invasion. Scale bar: 50 μm. I, Expression of epithelial markers, E‐cadherin and ZO‐1, and mesenchymal markers, vimentin, was analyzed by Western blotting in vector or CUL4B‐transfected JHU‐012 cells. J, Expression of epithelial markers, E‐cadherin and ZO‐1, and mesenchymal markers, vimentin, was analyzed by Western blotting in sh con or sh CUL4B JHU‐012 cells. * P < 0.05; ** P < 0.01

Article Snippet: The human HNSCC tissue microarrays (paraffin‐embedded), including follow‐up survival information, were provided by SuperBioChips.

Techniques: Transfection, Plasmid Preparation, Over Expression, Knockdown, Expressing, Western Blot

Journal: Cancer Medicine

Article Title: CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/β‐catenin signaling pathway

doi: 10.1002/cam4.1960

Figure Lengend Snippet: CUL4B enhances Wnt/β‐catenin signaling in HNSCC cells. A, mRNA level of β‐catenin, cyclin D1, c‐myc, and MMP7 in vector or CUL4B overexpressed JHU‐012 cells was determined by qRT‐PCR. B, mRNA level of β‐catenin, cyclin D1, c‐myc, and MMP7 in sh con or sh CUL4B JHU‐012 cells was determined by qRT‐PCR. C, Protein level of β‐catenin, cyclin D1, c‐myc, and MMP7 in the indicated group was determined by qRT‐PCR and Western blotting. (D) Levels of the active form of β‐catenin in JHU‐012 cells with knockdown or overexpression of CUL4B. E and F, The activity of TCF/β‐catenin reporter (TOP/FOP Flash) in CUL4B‐knockdown (E) and CUL4B‐overexpressing cells (F). * P < 0.05; ** P < 0.01

Article Snippet: The human HNSCC tissue microarrays (paraffin‐embedded), including follow‐up survival information, were provided by SuperBioChips.

Techniques: Plasmid Preparation, Quantitative RT-PCR, Western Blot, Knockdown, Over Expression, Activity Assay

Journal: Cancer Medicine

Article Title: CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/β‐catenin signaling pathway

doi: 10.1002/cam4.1960

Figure Lengend Snippet: Wnt/β‐catenin signaling regulates CUL4B functions in HNSCC cells Effects of XAV‐939, on CUL4B‐enhanced cell proliferation (A), migration (B), and invasion (C). Scale bar: 50 μm. Cells were treated with XAV‐939 or DMSO during the migration and invasion assays. ** P < 0.01

Article Snippet: The human HNSCC tissue microarrays (paraffin‐embedded), including follow‐up survival information, were provided by SuperBioChips.

Techniques: Migration

Journal: PLOS ONE

Article Title: CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma

doi: 10.1371/journal.pone.0281873

Figure Lengend Snippet: (A) Immunohistochemical staining with antibody against CDCP1 was performed to evaluate CDCP1 expression on the tissue arrays of UC. IHC tissues were observed and photographed at 40X magnification with an optical microscope (Olympus, Tokyo, Japan). Images were representative of negative, weak, moderate and strong CDCP1 staining at specimens of the normal, low grade, and high grade. (B) The intensity of CDCP1 expression was correlated with tumor grade. (C) The staining percentage of CDCP1 was correlated with tumor grade. (D) The product of the intensity and staining percentage of CDCP1 was correlated with tumor grade. Scale bar indicates 50 μm. Statistical analyses were evaluated by one-way ANOVA with Tukey’s multiple comparisons test. The results were presented as mean ± SD (normal n = 16; low grade n = 76; high grade n = 57, * p < 0.05, ** p < 0.01, *** p < 0.001).

Article Snippet: For IHC of CDCP1, paraffin-embedded human bladder tissue microarray slides were purchased from Biomax (BLC1501, BL601a, and BL208, Biomax Inc., Rockville, MD, USA).

Techniques: Immunohistochemical staining, Staining, Expressing, Microscopy

Journal: PLOS ONE

Article Title: CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma

doi: 10.1371/journal.pone.0281873

Figure Lengend Snippet: Urine-based cells of UC patients were collected from NCKUH. CDCP1 ICC was performed by using its specific antibody as described in “Material and methods”. (A) Increased CDCP1 was observed in UC specimen. (B) The CDCP1 ICC images of three UC patients were presented. The criteria to evaluate CDCP1 expression were indicated as negative (ICC intensity = 0), weak (ICC intensity = 1), moderate (ICC intensity = 2) and strong (ICC intensity = 3). Images of tissue specimen and urine cytology were taken at 400x magnification. Scale bar indicates 50 μm.

Article Snippet: For IHC of CDCP1, paraffin-embedded human bladder tissue microarray slides were purchased from Biomax (BLC1501, BL601a, and BL208, Biomax Inc., Rockville, MD, USA).

Techniques: Expressing

Journal: PLOS ONE

Article Title: CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma

doi: 10.1371/journal.pone.0281873

Figure Lengend Snippet: Cell lysates were collected from (A) 5637 and T24 cells or from (B) parental and 5637-CD cells to perform Western blot for detecting CDCP1, n-cadherin, e-cadherin, MMP2, and β -actin. (C) Parental and 5637-CD cells were harvested to seed on the upper chamber of Transwell ® , then the abilities of migration were measured as described in the “Materials and methods” section. Images of migration were taken at 200x magnification. Scale bar indicates 100 μm. In addition, T24 cells were transfected the CDCP1 specific shRNA plasmids for 24 hrs, and then harvested for the detection of (D) mRNA level, or (E) protein level of EMT markers, respectively. (F) Besides, the migration abilities of CDCP1-silenced T24 cells and parental cells were measured as described in “Materials and methods” section. Images of migration were captured at 400x magnification. Scale bar indicates 50 μm. Statistical analysis were analyzed by unpaired two-tailed Student’s t-test. The results were presented as mean ± SD (n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001).

Article Snippet: For IHC of CDCP1, paraffin-embedded human bladder tissue microarray slides were purchased from Biomax (BLC1501, BL601a, and BL208, Biomax Inc., Rockville, MD, USA).

Techniques: Western Blot, Migration, Transfection, shRNA, Two Tailed Test

Journal: PLOS ONE

Article Title: CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma

doi: 10.1371/journal.pone.0281873

Figure Lengend Snippet: Urine-based cytology is non-invasive and widely used for clinical diagnosis of UC, but its sensitivity is less than 40% for low-grade UC detection. We found a new biomarker CDCP1, which plays a critical role in the progression of UC and significantly increases in low-grade UC. We suggest CDCP1 may have potential as a urine-based biomarker for detecting low-grade UC in urinary cytology.

Article Snippet: For IHC of CDCP1, paraffin-embedded human bladder tissue microarray slides were purchased from Biomax (BLC1501, BL601a, and BL208, Biomax Inc., Rockville, MD, USA).

Techniques: Biomarker Discovery